A new vaccine to fight COVID-19 provided promising results among the first 45 people it was tested on according to results published Tuesday in the New England Journal of Medicine.
The vaccine, mRNA-1273, was administered to healthy adults aged 18-55 in two doses, 28 days apart. No serious adverse effects were reported by the trial participants, though some reported fatigue, headache, chills or pain at the injection site.
The vaccine prompted an immune system antibody response to the coronavirus in participants. It works by encouraging the development of antibodies which interact with the coronavirus spike protein.
Read more on themighty.com